Neoadjuvant chemotherapy combined with trastuzumab
(H) and pertuzumab (P) signifcantly improves the pathologic complete response (pCR) rate in HER2-positive breast
cancer.1
Previous studies have shown that hematologic markers, such as neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio, are associated with pCR; 2,3
however,
the relationship between serum enzymes and pCR remains
unclear. Given the ease of obtaining and analyzing serum
enzyme levels, we sought to explore their potential role in
predicting pCR in patients receiving neoadjuvant chemotherapy with dual-targeted therapy.
基金：
Natural Science Foundation of Sichuan Province [2023NSFSC0548]; Wu Jieping Medical Foundation [320.6750.2023-18-99]; China Primary Health Care Foundation [cphcf-2023-158]; National Natural Science Foundation of China [82003522]
第一作者机构：[1]Chengdu Univ Tradit Chinese Med, Sch Med & Life Sci, Chengdu, Peoples R China[2]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Sichuan Canc Ctr,Dept Breast Surg, Chengdu, Sichuan, Peoples R China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Chen Zongshun,Zhang Jing,Chen Wei,et al.ASO Author Reflections: Serum Enzymes as Predictive Biomarkers for Pathologic Complete Response in HER2-Positive Breast Cancer[J].ANNALS OF SURGICAL ONCOLOGY.2025,doi:10.1245/s10434-025-17259-z.
APA：
Chen, Zongshun,Zhang, Jing,Chen, Wei,Chen, Xueyi,Lu, Da-Lin&Li, Junjie.(2025).ASO Author Reflections: Serum Enzymes as Predictive Biomarkers for Pathologic Complete Response in HER2-Positive Breast Cancer.ANNALS OF SURGICAL ONCOLOGY,,
MLA：
Chen, Zongshun,et al."ASO Author Reflections: Serum Enzymes as Predictive Biomarkers for Pathologic Complete Response in HER2-Positive Breast Cancer".ANNALS OF SURGICAL ONCOLOGY .(2025)
